Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma

Oncotarget

Volumn 6, Issue 11, 2015, Pages 9551-9563

  Li, Jun ^a   Cheng, Zhang Jun ^b   Liu, Yang ^a   Yan, Zhen Lin ^a   Wang, Kui ^a   Wu, Dong ^a   Wan, Xu Ying ^a   Xia, Yong ^a   Lau, Wan Yee ^a,c   Wu, Meng Chao ^a   Shen, Feng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c Prince of Wales Hospital   (Hong Kong)

Author keywords

Biomarker; Chinese; Diagnosis; Hepatocellular carcinoma; Thioredoxin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; GLUTAMATE AMMONIA LIGASE; HEAT SHOCK PROTEIN 70; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIOREDOXIN; THIOREDOXIN REDUCTASE; TUMOR MARKER; AFP PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHINA; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; TUMOR VOLUME; BIOLOGICAL MODEL; BLOOD; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; EARLY DIAGNOSIS; LIVER DISEASE; LIVER NEOPLASMS; MIDDLE AGED;

ALPHA-FETOPROTEINS; AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CHINA; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; THIOREDOXINS; TUMOR BURDEN;

EID: 84928740690     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3314     Document Type: Article

References (51)

1. Chen J G, Zhang S W. Liver cancer epidemic in China:past, present and future[C]//Seminars in cancer biology. Academic Press 2011; 21: 59-69.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Xu Y, Liu A J, Gao Y X, Hu MG, Zhao GD, Zhao ZM, Liu R. Expression of Ku86 and Presence of Ku86 Antibody as Biomarkers of Hepatitis B Virus Related Hepatocellular Carcinoma. Digestive diseases and sciences, 2014; 59:614-622.
4. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361:1437-1447.
5. Zinkin N T, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clinical Cancer Research. 2008; 14:470-477.
6. Yang L, Rong W, Xiao T, Zhang Y, Xu B, Liu Y, Wang L, Wu F, Qi J, Zhao X, Wang H, Han N, Guo S, et al. Secretory/releasing proteomebased identification of plasma biomarkers in HBV-associated hepatocellular carcinoma. Sci China Life Sci. 2013; 56:638-646.
7. Tameda M, Shiraki K, Sugimoto K, Ogura S, Inagaki Y, Yamamoto N, Ikejiri M, Takei Y, Ito M, Nobori T. Desgamma-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma. Cancer Sci 2013; 104:725-731.
8. Paul D, Biswas R, Habib SH. Tissue polypeptide specific antigen as a marker used to determine the liver diseases. Kathmandu Univ Med J (KUMJ). 2011; 9:24-27.
9. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125:89-97.
10. Taketa K. a-Fetoprotein: reevaluation in hepatology. Hepatology 1990; 12:1420-1432.
11. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5:145-159.
12. Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, et al. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Molecular and cellular biology 2004; 24:9414-9423.
13. Bindoli A, Rigobello MP, Scutari G, et al. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coordination Chemistry Reviews 2009; 253:1692-1707.
14. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 2001; 41:261-295.
15. Kakisaka Y, Nakashima T, Sumida Y, Yoh T, Nakamura H, Yodoi J, Senmaru H. Elevation of serum thioredoxin levels in patients with type 2 diabetes. Hormone and metabolic research 2002; 34:160-164.
16. Tsuchikura S, Shoji T, Shimomura N, Kakiya R, Emoto M, Koyama H, Ishimura E, Inaba M, Nishizawa Y. Serum C-reactive protein and thioredoxin levels in subjects with mildly reduced glomerular filtration rate BMC nephrology. 2010; 11:7.
17. Abdiu A, Nakamura H, Sahaf B, Yodoi J, Holmgren A, Rosén A. Thioredoxin blood level increases after severe burn injury. Antioxidants and redox signaling 2000; 2:707-716.
18. Miyamoto S, Kawano H, Sakamoto T, Soejima H, Kajiwara I, Hokamaki J, Hirai N, Sugiyama S, Yoshimura M, Yasue H, Nakamura H, Yodoi J, Ogawa H. Increased plasma levels of thioredoxin in patients with coronary spastic angina Antioxidants and Redox Signaling. 2004; 6:75-80.
19. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The Redox Protein Thioredoxin-1 (Thioredoxin-1) Increases Hypoxiainducible Factor 1α Protein Expression Thioredoxin-1 Overexpression Results in Increased Vascular Endothelial Growth Factor Production and Enhanced Tumor Angiogenesis. Cancer research 2002; 62:5089-5095.
20. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC, Harris AL. Thioredoxin expression is associated with lymph node status and prognosis in early operable nonsmall cell lung cancer. Clin Cancer Res 2001; 7:3087-3091.
21. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003; 142:46-51.
22. Miyazaki K, Noda N, Okada S, Hagiwara Y, Miyata M, Sakurabayashi I, Yamaguchi N, Sugimura T, Terada M, Wakasugi H. EIevated serum level of Thioredoxin in patients with Hepatocellular Carcinoma. Biotherapy 1998; 11:277-288.
23. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008; 14:470-477.
24. Park BJ, Cha MK, Kim IH. Thioredoxin 1 as a serum marker for ovarian cancer and its use in combination with CA125 for improving the sensitivity of ovarian cancer diagnoses. Biomarkers 2014; 19:604-610.
25. Jeng JE, Tsai MF, Tsai HR, Chuang LY, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Tsai JF. Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma. Tumor Biology 2014; 35:3689-3698.
26. Shen Q, Fan J, Yang X R, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. The lancet oncology 2012; 13:817-826.
27. Marrero J A, Romano P R, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma Journal of hepatology. 2005; 43:1007-1012.
28. Cheng ZX, Huang XH, Wang Q, Chen JS, Zhang LJ, Chen XL. Clinical significance of decreased nidogen-2 expression in the tumor tissue and serum of patients with hepatocellular carcinoma. Journal of surgical oncology 2012; 105:71-80.
29. Di Tommaso L, Destro A, Fabbris V, Spagnuolo G, Laura Fracanzani A, Fargion S, Maggioni M, Patriarca C, Maria Macchi R, Quagliuolo M, Borzio M, Iavarone M, Sangiovanni A, et al. Diagnostic performance of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 2011; 53:1549-1557.
30. Nakagawa T, Seki T, Shiro T, Imamura M, Itoh T, Tamai T, Nishimura A, Yamashiki N, Matsuzaki K, Sakaida N, Inoue K, Okamura A. Clinicopathologic significance of protein induced by vitamin k absence or antagonistic II and alphafetoprotein in hepatocellular carcinoma. Int J Oncol 1999; 14:281-286.
31. Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P, Antonaci S. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer 2005; 117:506-509.
32. Meng FL, Wang W, Jia WD. Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma. Medical Oncology 2014; 31:1-6.
33. Zhang Z, Ge S, Wang X, et al. Serum miR-483-5p as a potential biomarker to detect hepatocellular carcinoma. Hepatology International 2013; 7:199-207.
34. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008; 5:588-99.
35. Witjes C DM, van Aalten SM, Steyerberg EW, Borsboom GJ, de Man RA, Verhoef C, Ijzermans JN. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology international 2013; 7:59-64.
36. Sumida Y, Nakashima T, Yoh T, Nakajima Y, Ishikawa H, Mitsuyoshi H, Sakamoto Y, Okanoue T, Kashima K, Nakamura H, Yodoi J. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 2000; 33:616-622.
37. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radical Biology and Medicine 2000; 29:312-322.
38. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, Fujii S, Ozawa K, Yodoi J. Expression and growth-promoting effect of adult t-cell leukemia-derived factor a human thioredoxin homologue in hepatocellular carcinoma Cancer. 1992; 69:2091-2097.
39. Jordan A, Reichard P. Ribonucleotide reductases. Annual review of biochemistry. 1998; 67:71-98.
40. Spector A, Yan GZ, Huang RR, McDermott MJ, Gascoyne PR, Pigiet V. The effect of H2O2 upon thioredoxin-enriched lens epithelial cells. Journal of Biological Chemistry 1988; 263:4984-4990.
41. Björnstedt M, Xue J, Huang W, Akesson B, Holmgren A. The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase. Journal of Biological Chemistry 1994; 269:29382-29384.
42. Iwata S, Hori T, Sato N, Hirota K, Sasada T, Mitsui A, Hirakawa T, Yodoi J. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state. The Journal of Immunology 1997; 158:3108-3117.
43. Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, Nakajima Y, Ishikawa H, Mitsuyoshi H, Okanoue T, Kashima K, Nakamura H, Yodoi J. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease J Hepatol 2003; 38:32-38.
44. Tamai T, Uto H, Takami Y, Oda K, Saishoji A, Hashiguchi M, Kumagai K, Kure T, Mawatari S, Moriuchi A, Oketani M, Ido A, Tsubouchi H. Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma. World J Gastroenterol 2011; 17:4890-4898.
45. Zhang XY, Chen DC, Xiu MH, Yang FD, Tan YL, He S, Kosten TA, Kosten TR. Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophrenia research 2013; 143:301-306.
46. Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, Yang Z, Cai J, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010; 59:1687-1693.
47. Tsai JF, Chang WY, Jeng JE, Wang LY, Hsieh MY, Chen SC, et al. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 1993; 41:296-300.
48. Pugh RN, Murray-Lyon IM, Dawson JL, Peitroni MC, Williams R. Transection of the esophagus for bleeding esophageal varices. Br J Surg 1973; 60:646-649.
49. Edmondson HA, Steiner PE. Primary carcinoma of the live. A study of 100 cases among 48, 900 necropsies. Cancer 1954; 7:462-503.
50. American Liver Tumor Study Group: A randomized prospective multi-institutional trial of orthotopic liver transplantation or partial hepatic resection with or without adjuvant chemotherapy for hepatocellular carcinoma. Investigators Booklet and Protocol. 1998; United Network for Organ Sharing Policy 3.6.4.4.
51. International Consensus Group for Hepatocellular Neoplasia: Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49:658-664.